A1c = glycohemoglobin A1c'; GMB = gut (large bowel) microbiota; DM2 = diabetes mellitus type 2; HOMA-IR = homeostatic model assessment -insulin resistance; LPS = lipopolysaccharide; RTC = Randomized controlled trial.
INTRODUCTION
Nutrition affects health and disease. Homo sapiens have evolved ~100,000 years ago in an environment with sporadic food availability favoring evolutionary selection of "thrifty" genes promoting preservation and storage of nutrients (1). Leap to the present and nutrient abundance instigates human obesity of epidemic proportion. The consequences of obesity, diabetes mellitus type 2 (DM2), non-alcoholic fatty liver disease (NAFLD) or steato-hepatitis (NASH), cardiovascular disease (CVD), and cancer, are main causes of morbidity and mortality in developed countries (2, 3) . Humans have coevolved with microbacteria, the first form of life to appear on Earth ~3.5 billion years ago (4) . Bacteria in the gut are called gut microbiota (called GMB or microbiota for the purpose of this review). "Microbiota" comes from Greek "mikros" meaning small and "bios" meaning life. Emerging evidence suggest an essential role of microbiota in human health and disease including digestion, energy and glucose metabolism, as well as immunomodulation and brain function (4) (5) (6) (7) (8) (9) . Diet-related interventions causing beneficial changes of GMB could also include prebiotics, probiotics and synbiotics (combining prebiotics and probiotics). There are many challenges in studying the usefulness of pre-, pro-and synbiotics for the human health. Multiple hypotheses still studies is beyond the scope of this manuscript. Numerous original papers and reviews of the preclinical data have been published (4-9,11,13,17,18).
Randomized controlled trials in subjects with obesity and prediabetes (19-24) as well as patients with DM2 (25-27) ( Table 1) showed inconsistent results with predominantly neutral effect on all evaluated metabolic parameters including body weight, BMI, fasting and postprandial glucose and insulin, glycohemoglobin A1c (A1c) and HOMA-IR (19-27). Similarly, variable results were produced for lipid profile with some studies showing reduced total cholesterol (24,26), low density lipoprotein (LDL) (20,26), and triglycerides (TG) (24,26) but with the majority of the studies showing no effect on lipid profile (19-24, 26) (Table 1) . Subclinical inflammation markers appear to be reduced (24-27), sometimes substantially. For example, markers were decreased as follows: hsCRP -35.6% (26), TNF-α -20-23% (26,27), lipopolysaccharide (LPS) -22-28% (26,27), marker of oxidative stress malondialdehyde -37.2% (25). Conversely, antioxidant defense (total antioxidant capacity) was increased +18.8% (25). In one trial including 16 healthy adults, a single evening meal of brown beans compared with white wheat bread (WWB, reference product) produced significant and clinically relevant improvement of glycemic and inflammatory markers (28). The effects shown at a subsequent standardized breakfast included lowered blood glucose (-15%, p<0.01) and insulin (-16%, p<0.05), increased satiety hormones (PYY +51% and GLP-2 +8.4%, p<0.05 for both), decreased hunger hormone (ghrelin -14%, p<0.05), hunger sensations (-15%, p = 0.05), and suppressed inflammatory markers (IL-6 -35% and IL-18 -8.3%, p<0.05 for both). An increase in breath H 2 (+141%, p<0.01), propionate (+16%, p<0.05), and isobutyrate (+18%, P<0.001) were significant after brown beans compared to after WWB, indicating involvement of colonic fermentation (28).
The results of various studies were confirmed by a recent meta-analysis that 
Availability
The raw natural food particularly rich in prebiotics (percent content by weight) include chicory root (~65%), Jerusalem artichoke (~32%), barley (22%), garlic (~18%), onion (~10%), globe artichoke (~7%), rye bran or grain (~7%), wheat bran (~5%), and asparagus (4%), and cooked food are chocolate (9%) and white bread (~3%) (30).
There are no published guidelines for daily prebiotics intake. Four to 10 g daily is suggested to be beneficial (11, 12) . Some examples of common food to achieve 6 g serving of prebiotics are as follows (amount [calories]): raw Jerusalem artichoke 19 g (15 kcal), raw garlic 34.3 g (45 kcal), raw leek 51.3 g (32 kcal), raw onion 70 g (20 kcal), and chemokines (4-9,32). The majority of known probiotics is species of human microbiota and expected to have the same functions as symbiotic microbiota (4-9,17,18).
Research data (Table 1)
Preclinical studies in cell lines and animal models reported possible probiotic usefulness for weight loss, insulin resistance and hyperlipidemia management (32-35).
An investigation of metabolism-related mechanisms of probiotic action showed ability to hydrolyze bile salts, to reduce fat accumulation and systemic inflammation, to decrease plasma leptin, and down-regulate peroxisome proliferator-activated receptor-γ (PPAR-γ) in the liver (32-35). These data need further confirmation.
The majority of RCTs of probiotics were small (less than 100 participants), of short duration (12 weeks or less) and used yogurt or capsules containing probiotics (Table 1) . The results showed non-significant or small, clinically irrelevant changes in body weight, blood pressure, A1c and other biomarkers including waist circumference, visceral fat, basal metabolic rate, lipid profile, HOMA-IR, insulin sensitivity index, and inflammation (CRP, IL-6, TNF-α) (Table 1) body weight and BMI and were not effective for weight loss (56). In contrast, a metaanalysis of 614 patients (from 11 RCTs) with DM2 pooled results showed a decrease in A1c (%) and fasting glucose (mg/dl): SMD -0.32; 95% CI -0.57, -0.07, P = 0.01 and SMD -9.36; 95% CI -16.56, -1.98, P =0.01 for A1c and glucose, respectively (57). There was, however, no effect on fasting insulin and HOMA-IR (57). In a meta-analysis of probiotics use for lipid lowering and other CVD risks (15 studies with 788 subjects), statistically significant pooled effects were found on reduction of BMI, waist circumference, total cholesterol, LDL, and inflammatory markers (58). However, the mean reductions were small, averaging 0.3 kg/m 2 for BMI, 1.82 cm for waist circumference, and ~10% for total cholesterol and LDL. Subgroup analysis revealed statistically significant effects of probiotics on total cholesterol and LDL when the medium was fermented milk or yogurt rather than a capsule form, consumption was at least 8 weeks in duration, and the probiotics consisted of multiple strains rather than a single strain. Among single strains, Lactobacillus gasseri was predominantly associated with weight loss (29) and Lactobacillus Acidophilus with reduction in LDL (58). There were inconsistencies and contradictions in observations depending on variability of a strain or strains of probiotics, dosage, duration of treatment and patient population.
Overall, it can be concluded that current results demonstrated small, if any, changes in body weight (< 3%) and metabolic parameters suggesting low clinical relevance and lack of evidence for using probiotics for weight loss or metabolic benefits. for pickled vegetables and a trial for fermented soy is unconvincing (60).
PREBIOTICS, PROBIOTIC, SYNBIOTICS AND MORBIDITY OR MORTALITY RISK
There are no randomized trials to answer the ultimate question of whether prebiotics, probiotics or synbiotics decrease morbidity or mortality risk. Prospective cohort studies of prebiotic-containing food (whole grains, fruits and vegetables)
unequivocally associate higher intake with decreased mortality risk in populations without and with diabetes (61-65). Probiotics are more difficult to assess due to variable fat content in fermented dairy and variable salt and acidity content in fermented vegetables. A few large prospective studies have evaluated relationship between fermented food intake and mortality. In a prospective cohort of 34,409 Dutch men and women followed for ~15 years, higher intake of fermented foods (predominantly dairy) was associated with moderately decreased risk of CVD mortality (66) . In this study CVD mortality, and particularly stroke mortality was reduced in highest vs. lowest quartile of fermented milk intake with hazard ratio [HR] 0.6, 95% CI 0.38-0.92 (p for trend 0.046) (66) . Similarly, meta-analysis of prospective cohort studies (764,635 participants)
showed that higher intake of fermented dairy was associated with reduced risk of stroke (relative risk 0.8, 95% CI 0.71-0.89) (67) . Fermented dairy intake was inversely associated with all-cause mortality in a prospective cohort of 4,526 participants followed for 10 years from Whitehall London civil servants study (68) but no relationship was observed in Dutch cohort (66) . Non-fermented soy was associated with lower risk of gastric and prostate cancer while fermented soy was neutral in a large prospective cohort (30,792 participants followed for 16 years) (69) and in a meta-analysis of epidemiologic studies (70) . A relatively large prospective cohort study (3, 158 participants followed for 18 years) suggested lower risk of cancer with higher intake of pickled vegetables (71) . There were no prospective cohort studies evaluating relationship between fermented soy or pickled vegetables and CVD or all-cause mortality.
RECOMMENDATIONS FOR INTAKE
Fiber is a main source of prebiotics in American diet. Average reported fiber and inulin intakes are 12.5 -18 g/day (72) and 1.3 -3.5 g/day (73), respectively, both lower than recommended. For fiber the Recommended Adequate Intake (RAI) is 25 -38 g/day (14 g/1,000 kcal/day) for all adults (74) and 25 -50 g/day for DM2 (75) corresponding to the AACE-recommended 7 -10 servings/day of "healthful" carbohydrates (2 
